Verve Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Verve Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
  • Verve Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 27.8 %, a 14.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 27.8 +3.6 +14.9% Jun 30, 2024
Q1 2024 27.4 +6.09 +28.5% Mar 31, 2024
Q4 2023 27.2 +9.89 +57% Dec 31, 2023
Q3 2023 26.6 +13.7 +106% Sep 30, 2023
Q2 2023 24.2 +17 +237% Jun 30, 2023
Q1 2023 21.3 +15.2 +244% Mar 31, 2023
Q4 2022 17.4 Dec 31, 2022
Q3 2022 12.9 Sep 30, 2022
Q2 2022 7.19 Jun 30, 2022
Q1 2022 6.2 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.